GSK_ Annual_Report_2021-22

During the pandemic, patients with acute respiratory diseases were amongst the most susceptible. They chose to stay away from hospitals and active administering of their medication due to the additional risk posed by Covid. Consequently, their health often deteriorated. To address this challenge, the Nucala auto-injector pen was launched. It is a first-of-its-kind device for severe eosinophilic asthma (SEA) patients in India. The ready-to-use device provided a more convenient way for patients, caregivers and HCPs to administer the dose. We are also readying for the launch of Shingrix, our shingles (Herpes zoster) vaccine in the coming year. This will give an option to patients who are immunocompromised, aged 50+ years, to stay protected against this painful disease. GSK is committed to helping patients combat shingles and its complications by bringing them a vaccine option that can prevent this painful condition. Trelegy Ellipta, is a single-inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients in a once-daily regime. The product was approved by the Drugs Controller General of India (DCGI) as a maintenance treatment to prevent and relieve symptoms associated with COPD patients aged 18 and above. It will enable a greater number of COPD patients in India to benefit from this world-leading medicine. Trelegy Ellipta exemplifies GSK’s ambition for patients and offers an example of how our innovative use of science and technology can help us get ahead of disease. This triple-drug therapy is an equally remarkable discovery. Severe asthma science animation 9 Financial Statements Statutory Reports Strategic Priorities Corporate Overview